Clinical Trial Update: Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on INO-4700 for Middle East respiratory syndrome (MERS) showing safety, tolerability, and immunogenicity in healthy volunteers. Re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Middle East Respiratory Syndrome

Drugs mentioned

• INO-4700

Snippet

Sponsor: Inovio Pharmaceuticals | Conditions: Middle East Respiratory Syndrome Coronavirus (MERS-CoV) | Phase 2 | Status: COMPLETED | Results posted: 2026-01-22